Associated Papers
Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib.
Zwierenga F et al.
Targeted Oncology, 2025
40473885 (PubMed )
Supplement: 11523_2025_1153_MOESM1_ESM.xlsx › Blad1
Select a paper to view details